On 2/29/24, Revance Therapeutics Inc (NASDAQ: RVNC) stock enjoyed a major increase of 26.1%, closing at $7.14. Moreover, this advance was accompanied by exceptionally high trading volume at 437% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 33.0% during the last week.
Current PriceTarget Research Rating
RVNC is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Revance Therapeutics has a very low Appreciation Score of 0 and a very low Power Rating of 0, with the Lowest Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment